Skip to main content

Table 4 Multivariate cox analyses of biomarkers and clinical factors with OS

From: Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy

 

High-grade serous carcinoma

Clear cell carcinoma

Factors

Hazard Ratio (95% CI)

HGSC P

Hazard Ratio (95% CI)

CCC P

Stage

 Early(I + II)

1.000

 

1.000

 

 Late(III + IV)

3.320(0.965–11.427)

0.057

9.703(2.588–36.381)

0.001

Residual tumor

  < 1 cm

1.000

 

1.000

 

  > 1 cm

1.367(0.560–3.339)

0.492

1.400(0.244–8.032)

0.706

Ascites

 No

1.000

 

1.000

 

 Yes

0.994(0.293–3.373)

0.993

2.587(0.848–7.890)

0.095

Chemotherapeutic response

 Sensitive

1.000

 

1.000

 

 Resistant

3.803(2.170–6.664)

0.000

3.562(1.063–11.936)

0.040

EGFR

 Negative

1.000

 

1.000

 

 Positive

1.244(0.653–2.370)

0.507

0.044(0.003–0628)

0.021

HER2

 Negative

1.000

 

1.000

 

 Positive

1.277(0.299–5.456)

0.741

7.948(1.745–36.208)

0.007

PTEN

 Negative

1.000

 

1.000

 

 Positive

0.696(0.257–1.880)

0.474

4.475(0.825–24.274)

0.082

AURKA

 Negative

1.000

 

1.000

 

 Positive

2.082(1.162–3.730)

0.014

1.763(0.616–5.044)

0.291

BRCA1

 Negative

1.000

 

1.000

 

 Positive

0.433(0.211–0.885)

0.022

1.934(0.653–5.738)

0.235

BRCA2

 Negative

1.000

 

1.000

 

 Positive

1.671(0.755–3.701)

0.206

1.258(0.352–4.493)

0.723

PD-L1

 Negative

1.000

 

1.000

 

 Positive

0.520(0.182–1.487)

0.222

1.157(0.387–3.456)

0.794

  1. CI confidence interval
  2. Bold value denotes P with statistical significance